WO2000039305A1 - PYRUVATE CARBOXYLASE PROVENANT DE $i(CORYNEBACTERIUM GLUTAMICUM) - Google Patents

PYRUVATE CARBOXYLASE PROVENANT DE $i(CORYNEBACTERIUM GLUTAMICUM) Download PDF

Info

Publication number
WO2000039305A1
WO2000039305A1 PCT/US1998/027301 US9827301W WO0039305A1 WO 2000039305 A1 WO2000039305 A1 WO 2000039305A1 US 9827301 W US9827301 W US 9827301W WO 0039305 A1 WO0039305 A1 WO 0039305A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyruvate carboxylase
amino acid
sequence
polynucleotide
polypeptide
Prior art date
Application number
PCT/US1998/027301
Other languages
English (en)
Inventor
Anthony J. Sinskey
Philip A. Lessard
Laura B. Willis
Original Assignee
Massachusetts Institute Of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute Of Technology filed Critical Massachusetts Institute Of Technology
Priority to MXPA01006290A priority Critical patent/MXPA01006290A/es
Priority to EP98966046A priority patent/EP1147198A1/fr
Priority to CA002356446A priority patent/CA2356446A1/fr
Priority to CN98814374A priority patent/CN1336958A/zh
Priority to JP2000591196A priority patent/JP2003503006A/ja
Priority to AU22033/99A priority patent/AU2203399A/en
Priority to BR9816106-7A priority patent/BR9816106A/pt
Priority to PCT/US1998/027301 priority patent/WO2000039305A1/fr
Priority to KR1020017007962A priority patent/KR20010112232A/ko
Publication of WO2000039305A1 publication Critical patent/WO2000039305A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/08—Lysine; Diaminopimelic acid; Threonine; Valine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y604/00—Ligases forming carbon-carbon bonds (6.4)
    • C12Y604/01—Ligases forming carbon-carbon bonds (6.4.1)
    • C12Y604/01001—Pyruvate carboxylase (6.4.1.1)

Definitions

  • the present invention relates to a Corynebacterium glutamicum pyruvate carboxylase protein and to polynucleotides encoding this protein.
  • Pyruvate carboxylate is an important anaplerotic enzyme replenishing oxaloacetate consumed for biosynthesis during growth, or lysine and glutamic acid production in industrial fermentations.
  • reaction (1) the ATP-dependent biotin carboxylase domain carboxylates a biotin prosthetic group linked to a specific lysine residue in the biotin-carboxyl-carrier protein (BCCP) domain.
  • BCCP biotin-carboxyl-carrier protein
  • Acetyl-coenzyme A activates reaction ( 1 ) by increasing the rate of bicarbonate-dependent ATP cleavage.
  • reaction (2) donates the
  • Pruvate carboxylase genes have been cloned and sequenced from: Rhizobium etli (Dunn, M.F., et al, J. Bacteriol 178:5960-5910 (1996)), Bacillus stearothermophilus (Kondo, H., et al, Gene 191:41-50 (1997).
  • Rhizobium etli Unn, M.F., et al, J. Bacteriol 178:5960-5910 (1996)
  • Bacillus stearothermophilus Korean, H., et al, Gene 191:41-50 (1997).
  • Bacillus subtillis Bacillus subtillis
  • the rate of lysine production is less than or equal to the rate of oxaloacetate synthesis via the anaplerotic pathways.
  • the present invention provides isolated nucleic acid molecules comprising a polynucleotide encoding a pyruvate carboxylase polypeptide having the amino acid sequence in Figure 1 (SEQ ID ⁇ O:2) or the amino acid sequence encoded by the cosmid clone deposited in a bacterial host as ATCC Deposit Number .
  • the 1 140 amino acid sequence of the predicted pyruvate carboxylase protein is shown in Figure 1 and in SEQ ID NO:2.
  • one aspect of the invention provides an isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence encoding the pyruvate carboxylase polypeptide having the complete amino acid sequence in SEQ ID NO:2; (b) a nucleotide sequence encoding the pyruvate carboxylase polypeptide having the complete amino acid sequence encoded by the cosmid clone contained in ATCC Deposit No. ; and (c) a nucleotide sequence complementary to any of the nucleotide sequences in (a) or (b) above.
  • nucleic acid molecules that comprise a polynucleotide having a nucleotide sequence at least 90%) identical, and more preferably at least 95%o, 97%>, 98%> or 99%> identical, to any of the nucleotide sequences in (a), (b) or (c) above, or a polynucleotide which hybridizes under stringent hybridization conditions to a polynucleotide having a nucleotide sequence identical to a nucleotide sequence in (a), (b) or (c), above.
  • the polynucleotide which hybridizes does not hybridize under stringent hybridization conditions to a polynucleotide having a nucleotide sequence consisting of only A residues or of only T residues.
  • the present invention also relates to recombinant vectors which include the isolated nucleic acid molecules of the present invention and to host cells containing the recombinant vectors, as well as to methods of making such vectors and host cells and for using them for production of pyruvate carboxylase polypeptides or peptides by recombinant techniques.
  • the invention further provides an isolated pyruvate carboxylase polypeptide having amino acid sequence selected from the group consisting of: (a) the amino acid sequence of the pyruvate carboxylase polypeptide having the amino acid sequence shown in Figure 1 (SEQ ID NO:2); and (b) the amino acid sequence of the pyruvate carboxylase polypeptide having the complete amino acid sequence encoded by the cosmid clone contained in ATCC Deposit No. .
  • polypeptides of the present invention also include polypeptides having an amino acid sequence with at least 90%> similarity, more preferably at least 95%o similarity to those described in (a) or (b) above, as well as polypeptides having an amino acid sequence at least 70% identical, more preferably at least 90% identical, and still more preferably 95%>, 97%, 98% or 99% identical to those above.
  • Figure 1 shows the nucleotide (SEQ ID NO: l) and deduced amino acid (SEQ ID NO:2) sequences of the complete pyruvate carboxylase protein determined by sequencing of the DNA clone contained in ATCC Deposit No. .
  • the protein has sequence of about 1 140 amino acid residues and a deduced molecular weight of about 123.6 kDa.
  • the present invention provides isolated nucleic acid molecules comprising a polynucleotide encoding the pyruvate carboxylase protein having the amino acid sequence shown in Figure 1 (SEQ ID NO:2) which was determined by sequencing a cloned cosmid.
  • the pyruvate carboxylase protein of the present invention shares sequence homology with M. tuberculosis and human pyruvate carboxylase proteins.
  • the nucleotide sequence shown in Figure 1 (SEQ ID NO:l) was obtained by sequencing cosmid III F10 encoding a pyruvate carboxylase polypeptide, which was deposited on at the American Type Culture Collection,
  • nucleotide sequences determined by sequencing a DNA molecule herein were determined using an automated DNA sequencer (such as the ABI Prism 377), and all amino acid sequences of polypeptides encoded by DNA molecules determined herein were predicted by translation of a DNA sequence determined as above. Therefore, as is known in the art for any DNA sequence determined by this automated approach, any nucleotide sequence determined herein may contain some errors. Nucleotide sequences determined by automation are typically at least about 90% identical, more typically at least about 95% to at least about 99.9%) identical to the actual nucleotide sequence of the sequenced DNA molecule. The actual sequence can be more precisely determined by other approaches including manual DNA sequencing methods well known in the art.
  • nucleotide sequence As is also known in the art, a single insertion or deletion in a determined nucleotide sequence compared to the actual sequence will cause a frame shift in translation of the nucleotide sequence such that the predicted amino acid sequence encoded by a determined nucleotide sequence will be completely different from the amino acid sequence actually encoded by the sequenced DNA molecule, beginning at the point of such an insertion or deletion.
  • each "nucleotide sequence" set forth herein is presented as a sequence of deoxyribonucleotides (abbreviated A, G . C and T).
  • nucleotide sequence of a nucleic acid molecule or polynucleotide is intended, for a DNA molecule or polynucleotide, a sequence of deoxyribonucleotides, and for an RNA molecule or polynucleotide.
  • sequence of ribonucleotides A, G, C and U
  • T thymidine deoxynucleotide
  • U ribonucleotide uridine
  • RNA molecule having the sequence of SEQ ID NO:l set forth using deoxyribonucleotide abbreviations is intended to indicate an RNA molecule having a sequence in which each deoxynucleotide A, G or C of SEQ ID NO: l has been replaced by the corresponding ribonucleotide A, G or C, and each deoxynucleotide T has been replaced by a ribonucleotide U.
  • a nucleic acid molecule of the present invention encoding a pyruvate carboxylase polypeptide may be obtained using standard cloning and screening procedures, such as those for cloning DNAs using mRNA as starting material.
  • the pyruvate carboxylase protein shown in Figure 1 (SEQ ID NO:2) is about 63% identical to M. tuberculosis and 44%o identical to human.
  • the actual pyruvate carboxylase polypeptide encoded by the deposited cosmid comprises about 1140 amino acids, but may be anywhere in the range of 1133-1147 amino acids.
  • nucleic acid molecules of the present invention may be in the form of RNA, such as mRNA, or in the form of DNA, including, for instance, cDNA and genomic DNA obtained by cloning or produced synthetically.
  • the DNA may be double-stranded or single-stranded.
  • Single-stranded DNA or RNA may be the coding strand, also known as the sense strand, or it may be the non-coding strand, also referred to as the anti-sense strand.
  • isolated nucleic acid molecule(s) is intended a nucleic acid molecule, DNA or RNA, which has been removed from its native environment.
  • recombinant DNA molecules contained in a vector are considered isolated for the purposes of the present invention.
  • Further examples of isolated DNA molecules include recombinant DNA molecules maintained in heterologous host cells or purified (partially or substantially) DNA molecules in solution.
  • Isolated RNA molecules include in vivo or in vitro RNA transcripts of the DNA molecules of the present invention. Isolated nucleic acid molecules according to the present invention further include such molecules produced synthetically.
  • Isolated nucleic acid molecules of the present invention include DNA molecules comprising an open reading frame (ORF) with an initiation codon at positions 199-201 of the nucleotide sequence shown in Figure 1 (SEQ ID NO:l); DNA molecules comprising the coding sequence for the pyruvate carboxylase protein shown in Figure 1 and SEQ ID NO:2; and DNA molecules which comprise a sequence substantially different from those described above but which, due to the degeneracy of the genetic code, still encode the pyruvate carboxylase protein.
  • ORF open reading frame
  • SEQ ID NO:l DNA molecules comprising the coding sequence for the pyruvate carboxylase protein shown in Figure 1 and SEQ ID NO:2
  • the genetic code is well known in the art. Thus, it would be routine for one skilled in the art to generate the degenerate variants described above.
  • the invention provides isolated nucleic acid molecules encoding the pyruvate carboxylase polypeptide having an amino acid sequence encoded by the cosmid clone deposited as ATCC Deposit No. .
  • this nucleic acid molecule will encode the polypeptide encoded by the above- described deposited clone.
  • the invention further provides an isolated nucleic acid molecule having the nucleotide sequence shown in Figure 1 (SEQ ID NO: 1 ) or the nucleotide sequence of the pyruvate carboxylase DNA contained in the above- described deposited clone, or nucleic acid molecule having a sequence complementary to one of the above sequences.
  • the invention provides an isolated nucleic acid molecule comprising a polynucleotide which hybridizes under stringent hybridization conditions to a portion of the polynucleotide in a nucleic acid molecule of the invention described above, for instance, the cosmid clone contained in ATCC Deposit .
  • stringent hybridization conditions is intended overnight incubation at 42 °C in a solution comprising: 50%o formamide, 5x SSC (150 mM NaCl, 15mM trisodium citrate), 50 niM sodium phosphate (pH7.6), 5x Denhardt's solution, 10%) dextran sulfate, and 20 ⁇ g/ml denatured, sheared salmon sperm DNA, followed by washing the filters in O. lx SSC at about 65 °C.
  • a polynucleotide which hybridizes to a "portion" of a polynucleotide is intended a polynucleotide (either DNA or RNA) hybridizing to at least about 15 nucleotides (nt), and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably about 30-70 nt of the reference polynucleotide. These are useful as diagnostic probes and primers.
  • polynucleotides hybridizing to a larger portion of the reference polynucleotide e.g., the deposited cosmid clone
  • a portion 50-750 nt in length, or even to the entire length of the reference polynucleotide also useful as probes according to the present invention, as are polynucleotides corresponding to most, if not all, of the nucleotide sequence of the deposited DNA or the nucleotide sequence as shown in Figure 1 (SEQ ID NO:l).
  • such portions are useful diagnostically either as a probe according to conventional DNA hybridization techniques or as primers for amplification of a target sequence by the polymerase chain reaction (PCR), as described, for instance, in Molecular Cloning, A Laboratory Manual, 2nd. edition, edited by Sambrook, J., Fritsch, E. F. and Maniatis, T., (1989), Cold Spring Harbor Laboratory Press, the entire disclosure of which is hereby incorporated herein by reference.
  • a pyruvate carboxylase cosmid clone has been deposited and its determined nucleotide sequence is provided in Figure 1 (SEQ ID NO: 1 )
  • generating polynucleotides which hybridize to a portion of the pyruvate carboxylase DNA molecule would be routine to the skilled artisan.
  • restriction endonuclease cleavage or shearing by sonication of the pyruvate carboxylase cosmid clone could easily be used to generate DNA portions of various sizes which are polynucleotides that hybridize to a portion of the pyruvate carboxylase DNA molecule.
  • the hybridizing polynucleotides of the present invention could be generated synthetically according to known techniques.
  • nucleic acid molecules of the present invention which encode the pyruvate carboxylase protein polypeptide may include, but are not limited to those encoding the amino acid sequence of the polypeptide, by itself; the coding sequence for the polypeptide and additional sequences, such as a pre-, or pro- or prepro- protein sequence; the coding sequence of the polypeptide, with or without the aforementioned additional coding sequences, together with additional, non-coding sequences, including for example, but not limited to introns and non- coding 5' and 3' sequences, such as the transcribed, non-translated sequences that play a role in transcription, mRNA processing - including splicing and polyadenylation signals, for example - ribosome binding and stability of mRNA; an additional coding sequence which codes for additional amino acids, such as those which provide additional functionalities.
  • the sequence encoding the polypeptide may be fused to a marker sequence, such as a sequence encoding a peptide which facilitates purification of the fused polypeptide.
  • the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (Qiagen, Inc.), among others, many of which are commercially available.
  • hexa-histidine provides for convenient purification of the fusion protein.
  • the "HA" tag is another peptide useful for purification which corresponds to an epitope derived from the influenza hemagglutinin protein, which has been described by Wilson et al. , Cell 57: 767 (1984).
  • the present invention further relates to variants of the nucleic acid molecules of the present invention, which encode portions, analogs or derivatives of the pyruvate carboxylase protein.
  • Variants may occur naturally, such as a natural allelic variant.
  • allelic variant is intended one of several alternate forms of a gene occupying a given locus on a chromosome of an organism.
  • Non-naturally occurring variants may be produced using art-known mutagenesis techniques.
  • Such variants include those produced by nucleotide substitutions, deletions or additions.
  • the substitutions, deletions or additions may involve one or more nucleotides.
  • the variants may be altered in coding or non-coding regions or both. Alterations in the coding regions may produce conservative or non- conservative amino acid substitutions, deletions or additions. Especially preferred among these are silent substitutions, additions and deletions, which do not alter the properties and activities of the pyruvate carboxylase protein or portions thereof. Also especially preferred in this regard are conservative substitutions.
  • nucleic acid molecules encoding the pyruvate carboxylase protein having the amino acid sequence shown in Figure 1 (SEQ ID NO:2).
  • nucleic acid molecules comprising a polynucleotide having a nucleotide sequence at least 90%) identical, and more preferably at least 95%o, 91%, 98%> or 99% identical to (a) a nucleotide sequence encoding the pyruvate carboxylase polypeptide having the complete amino acid sequence in SEQ ID NO:2; (b) a nucleotide sequence encoding the pyruvate carboxylase polypeptide having the complete amino acid sequence encoded by the cosmid clone contained in ATCC Deposit No. ; or
  • polynucleotide having a nucleotide sequence at least, for example,
  • nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the pyruvate carboxylase polypeptide.
  • a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence.
  • These mutations of the reference sequence may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence.
  • any particular nucleic acid molecule is at least 90%, 95%, 97%, 98% or 99% identical to, for instance, the nucleotide sequence shown in Figure 1 or to the nucleotides sequence of the deposited cosmid clone can be determined conventionally using known computer programs such as the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, WI 5371 1). Bestfit uses the local homology algorithm of Smith and Waterman (Advances in Applied Mathematics 2: 482-489 (1981)) to find the best segment of homology between two sequences. When using Bestfit or any other sequence alignment program to determine whether a particular sequence is.
  • the parameters are set, of course, such that the percentage of identity is calculated over the full length of the reference nucleotide sequence and that gaps in homology of up to 5% of the total number of nucleotides in the reference sequence are allowed.
  • the present application is directed to nucleic acid molecules at least 90%
  • nucleic acid sequence shown in Figure 1 SEQ ID NO: 1
  • nucleic acid sequence of the deposited DNA irrespective of whether they encode a polypeptide having pyruvate carboxylase activity. This is because, even where a particular nucleic acid molecule does not encode a polypeptide having pyruvate carboxylase activity, one of skill in the art would still know how to use the nucleic acid molecule, for instance, as a hybridization probe or a polymerase chain reaction (PCR) primer.
  • PCR polymerase chain reaction
  • nucleic acid molecules having sequences at least 90%), 95%o, 97%), 98%> or 99%o identical to the nucleic acid sequence shown in Figure 1 (SEQ ID NO: l) or to the nucleic acid sequence of the deposited DNA which do, in fact, encode a polypeptide having pyruvate carboxylase protein activity.
  • a polypeptide having pyruvate carboxylase activity is intended polypeptides exhibiting activity similar, but not necessarily identical, to an activity of the pyruvate carboxylase protein of the invention as measured in a particular biological assay.
  • nucleic acid molecules having a sequence at least 90%>, 95%>, 97%>, 98%>, or 99%> identical to the nucleic acid sequence of the deposited DNA or the nucleic acid sequence shown in Figure 1 (SEQ ID NO:l) will encode a polypeptide "having pyruvate carboxylase protein activity.”
  • degenerate variants of these nucleotide sequences all encode the same polypeptide, this will be clear to the skilled artisan even without performing the above described comparison assay.
  • nucleic acid molecules that are not degenerate variants, a reasonable number will also encode a polypeptide having pyruvate carboxylase protein activity. This is because the skilled artisan is fully aware of amino acid substitutions that are either less likely or not likely to significantly effect protein function (e.g., replacing one aliphatic amino acid with a second aliphatic amino acid).
  • the present invention also relates to vectors which include the isolated DNA molecules of the present invention, host cells which are genetically engineered with the recombinant vectors, and the production of pyruvate carboxylase polypeptides or portions thereof by recombinant techniques.
  • Recombinant constructs may be introduced into host cells using well known techniques such as infection, transduction, transfection, transvection, conjugation, electroporation and transformation.
  • the vector may be, for example, a phage, plasmid, viral or retroviral vector.
  • the polynucleotides may be joined to a vector containing a selectable marker for propagation in a host.
  • a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.
  • vectors comprising cis-acting control regions to the polynucleotide of interest.
  • Appropriate trans-acting factors may be supplied by the host, supplied by a complementing vector or supplied by the vector itself upon introduction into the host.
  • the vectors provide for specific expression, which may be inducible and/or cell type-specific. Particularly preferred among such vectors are those inducible by environmental factors that are easy to manipulate, such as temperature and nutrient additives.
  • Expression vectors useful in the present invention include chromosomal-, episomal- and virus-derived vectors, e.g., vectors derived from bacterial plasmids, bacteriophage, yeast episomes, yeast chromosomal elements, viruses such as baculoviruses, papova viruses, vaccinia viruses, adenoviruses. fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as cosmids and phagemids.
  • the DNA insert should be operatively linked to an appropriate promoter.
  • an appropriate promoter such as the phage lambda P L promoter, the E. coli lac, trp and lac promoters, the
  • the expression constructs will further contain sites for transcription initiation, termination and. in the transcribed region, a ribosome binding site for translation.
  • the coding portion of the mature transcripts expressed by the constructs will include a translation initiating codon (AUG or GUG) at the beginning and a termination codon appropriately positioned at the end of the polypeptide to be translated.
  • the expression vectors will preferably include at least one selectable marker.
  • markers include dihydrofolate reductase or neomycin resistance for eukaryotic cell culture and tetracycline, ampicillin. chloramphenicol or kanamycin resistance genes for culturing in E. coli and other bacteria.
  • Representative examples of appropriate hosts include bacterial cells, such as E. coli, C. glutamicum, Streptomyces and Salmonella typhimurium cells; fungal cells, such as yeast cells. Appropriate culture media and conditions for the above-described host cells are known in the art.
  • vectors preferred for use in bacteria include pA2, pQ ⁇ 70, pQE60 and pQE-9, available from Qiagen; pBS vectors, Phagescript vectors. Bluescript vectors, pNH8A, pNHl ⁇ a, pNH18A, pNH46A, available from Stratagene; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia.
  • eukaryotic vectors are p WLNEO, pS V2C AT, pOG44, pXT 1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia.
  • Other suitable vectors will be readily apparent to the skilled artisan.
  • bacterial promoters suitable for use in the present invention include the E. coli lacl and lacZ promoters, the T3 and T7 promoters, the gpt promoter, the lambda P R and P L promoters and the trp promoter.
  • Suitable eukaryotic promoters include the CMV immediate early promoter, the HSV thymidine kinase promoter, the early and late SV40 promoters, the promoters of retroviral LTRs, such as those of the Rous sarcoma virus (RSV), and metallothionein promoters, such as the mouse metallothionein-I promoter.
  • Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection. cationic lipid- mediated transfection. electroporation. transduction, infection or other methods.
  • Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp that act to increase transcriptional activity of a promoter in a given host cell-type.
  • enhancers include the SV40 enhancer, which is located on the late side of the replication origin at bp 100 to 270, the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adeno virus enhancers.
  • secretion signals may be incorporated into the expressed polypeptide.
  • the signals may be endogenous to the polypeptide or they may be heterologous signals.
  • the polypeptide may be expressed in a modified form, such as a fusion protein, and may include not only secretion signals, but also additional heterologous functional regions.
  • a region of additional amino acids, particularly charged amino acids may be added to the N-terminus of the polypeptide to improve stability and persistence in the host cell, during purification, or during subsequent handling and storage.
  • peptide moieties may be added to the polypeptide to facilitate purification.
  • the pyruvate carboxylase protein can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography. hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography (“HPLC”) is employed for purification.
  • HPLC high performance liquid chromatography
  • Polypeptides of the present invention include naturally purified products, products of chemical synthetic procedures, and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host- mediated processes.
  • the invention further provides an isolated pyruvate carboxylase polypeptide having the amino acid sequence encoded by the deposited DNA, or the amino acid sequence in Figure 1 (SEQ ID NO:2), or a peptide or polypeptide comprising a portion of the above polypeptides.
  • the terms "peptide” and “oligopeptide” are considered synonymous (as is commonly recognized) and each term can be used interchangeably as the context requires to indicate a chain of at least to amino acids coupled by peptidyl linkages.
  • polypeptide is used herein for chains containing more than ten amino acid residues. All oligopeptide and polypeptide formulas or sequences herein are written from left to right and in the direction from amino terminus to carboxy terminus.
  • the invention further includes variations of the pyruvate carboxylase polypeptide which show substantial activity or which include regions of pyruvate carboxylase protein such as the protein portions discussed below.
  • Such mutants include deletions, insertions, inversions, repeats, and type substitutions (for example, substituting one hydrophilic residue for another, but not strongly hydrophilic for strongly hydrophobic as a rule). Small changes or such "neutral" amino acid substitutions will generally have little effect on activity.
  • conservative substitutions are the replacements, one for another, among the aliphatic amino acids Ala, Val, Leu and He; interchange of the hydroxyl residues Ser and Thr, exchange of the acidic residues Asp and Glu, substitution between the amide residues Asn and Gin, exchange of the basic residues Lys and Arg and replacements among the aromatic residues Phe, Tyr.
  • polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified.
  • a recombinantly produced version of the pyruvate carboxylase polypeptide can be substantially purified by the one-step method described in Smith and Johnson, Gene (57:31-40 (1988).
  • polypeptides of the present invention include the polypeptide encoded by the deposited DNA, the polypeptide of SEQ ID NO:2, as well as polypeptides which have at least 90%> similarity, more preferably at least 95%) similarity, and still more preferably at least 97%o, 98%> or 99%> similarity to those described above.
  • Further polypeptides of the present invention include polypeptides at least 10% identical, more preferably at least 90%> or 95%> identical, still more preferably at least 97%, 98%> or 99%o identical to the polypeptide encoded by the deposited DNA, to the polypeptide of SEQ ID NO:2, and also include portions of such polypeptides with at least 30 amino acids and more preferably at least 50 amino acids.
  • % similarity for two polypeptides is intended a similarity score produced by comparing the amino acid sequences of the two polypeptides using the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison. WI 53711) and the default settings for determining similarity. Bestfit uses the local homology algorithm of Smith and Waterman (Advances in Applied Mathematics
  • polypeptide having an amino acid sequence at least, for example. 95%o "identical" to a reference amino acid sequence of a pyruvate carboxylase polypeptide is intended that the amino acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the reference amino acid of the pyruvate carboxylase polypeptide.
  • a polypeptide having an amino acid sequence at least 95%) identical to a reference amino acid sequence up to 5%> of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 5% of the total amino acid residues in the reference sequence may be inserted into the reference sequence.
  • These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.
  • any particular polypeptide is at least 90%>, 95%), 97%o, 98%o or 99% identical to, for instance, the amino acid sequence shown in Figure 1 (SEQ ID NO:2) or to the amino acid sequence encoded by deposited cosmid clone can be determined conventionally using known computer programs such the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive. Madison, WI 5371 1.
  • the parameters are set, of course, such that the percentage of identity is calculated over the full length of the reference amino acid sequence and that gaps in homology of up to 5% of the total l ⁇ number of amino acid residues in the reference sequence are allowed.
  • Corynebacterium researchers need to be able to identify and clone the genes that are involved in the target pathway. They also need methods for altering these genes to affect the regulation or level of expression of the enzymes they encode, and for subsequently reintroducing the altered genes into Corynebacterium to monitor their effects on amino acid biosynthesis. Therefore, metabolic engineers must have at their disposal an array of plasmids that can replicate in both Corynebacterium and other, more easily manipulated hosts, such as E. coli. Also required are a collection of selectable markers encoding, for example, antibiotic resistance, well-characterized transcriptional promoters that permit regulation of the altered genes, and efficient transformation or conjugation systems that allow the plasmids to be inserted into the target Corynebacterium strain.
  • Plasmids Plasmids. Several different plasmids have been isolated and developed for the introduction and expression of genes in Corynebacterium (Sonnen, H., et al, Gene 107:69-14 (1991)). The majority of these were originally identified as small (3-5 kbp), cryptic plasmids from C. glutamicum, C callunae, and C lactofermentum. They fall into four compatibility groups, exemplified by the plasmids pCCl , pBLl, pHM1519, and pGAl . Shuttle vectors, plasmids that are capable of replicating in both Corynebacterium and E. coli, have been developed from these cryptic plasmids by incorporating elements from known E.
  • coli plasmids (particularly the Col ⁇ l origin of replication from pBR322 or pUC 18), as well as antibiotic-resistance markers.
  • a fifth class of plasmids that is very useful for manipulating Corynebacterium is based on pNG2, a plasmid originally isolated from Corynebacterium diphtheriae (Serwold-Davis, T.M., et al, Proc. Nail. Acad. Sci. USA 54:4964-4968 ( 1987)). This plasmid and its derivatives replicate efficiently in many species of corynebacteria. as well as in E. coli.
  • pNG2 Since the sole origin of replication in pNG2 (an element of only 1.8 kbp) functions in both the Gram-positive and Gram- negative host, there is no need to add an additional Col ⁇ l -type element to it. As a result, pNG2 derivatives (e.g., p ⁇ P2) are much smaller than other Corynebacterium shuttle vectors and are therefore more easily manipulated.
  • Selectable Markers Several genes conferring antibiotic resistance have proven useful for plasmid selection and in other recombinant DNA work in corynebacteria. These include the kanamycin resistance determinant from TnP03. a hygromycin resistance marker isolated from Streptomyces hygroscopicus, a tetracycline resistance gene from Streptococcus faecalis, a bleomycin resistance gene from Tn5, and a chloramphenicol resistance marker from Streptomyces acrimycini. The ⁇ -lactamase gene that is employed in many E. coli plasmids such as pBR322 does not confer ampicillin resistance in Corynebacterium.
  • Transformation Systems Several methods have been devised for introducing foreign DNA into Corynebacterium. The earliest method to be employed routinely was based on protocols that had been successful for other Gram-positive species involving incubation of spheroplasts in the presence of DNA and polyethylene glycol (Yoshihama, M., etal.,J. Bacteriol. 7(52:591-597 (1985)). While useful, these methods were generally inefficient, often yielding fewer than 10 5 transformants per milligram of DNA. ⁇ lectroporation of Corynebacterium spheroplasts has proven to be a much more efficient and reliable means of transformation.
  • Spheroplasts are generated by growing the cells in rich media containing glycine and/or low concentrations of other inhibitors of cell wall biosynthesis, such as isonicotinic acid hydrazide (isoniazid). ampicillin, penicillin G, or Tween-80. The spheroplasts are then washed in low-salt buffers containing glycerol, concentrated, and mixed with DNA before being subjected to electroporation. Efficiencies as high as 10 7 transformants per microgram of plasmid DNA have been reported with this protocol.
  • a third method for DNA transfer into corynebacteria involves transconjugation. This method takes advantage of the promiscuity of E. coli strains carrying derivatives of the plasmid RP4.
  • RP4 encodes many functions that mediate the conjugal transfer of plasmids from the host strain to other recipient strains of E. coli, or even to other species. These "tra functions" mediate pilus formation and plasmid transfer.
  • RP4 also carries an origin of transfer, oriT, a -acting element that is recognized by the transfer apparatus that allows the plasmid to be conducted through the pilus and into the recipient strain. From this system Simon et al.
  • coli plasmid that carries the RP4 oriT but lacks an origin to support replication in Corynebacterium. SI 7-1 carrying this plasmid is then incubated with the recipient strain and the mixture is later transferred to a selective medium. Because the plasmid that was introduced is unable to replicate in corynebacteria, transconjugants that express the selectable marker are most likely to have undergone a cross-over recombination within the genomic DNA.
  • Integrons are DNA molecules that have the same restriction/modification properties as the target host's DNA, carry DNA that is homologous to a portion of the host genome (i.e.. a region of the genome that is to be disrupted), and are unable to replicate in the host cell.
  • a cloned gene from Corynebacterium is first interrupted with a selectable marker in a plasmid that is propagated in one Cornynebacterium strain. This construct is then excised from the corynebacterial plasmid and self-ligated to form a non-replicating circular molecule. This "integron" is then electroporated into the restrictive host. Modification of the DNA allows the integron to elude the host restriction system, and recombination into the host genome permits expression of the selectable marker.
  • Promoters Reliable transcriptional promoters are required for efficient expression of foreign genes in Corynebacterium. For certain experiments, there is also a need for regulated promoters whose activity can be induced under specific culture conditions. Promoters such as the fda, thrC, and horn promoters derived from Corynebacterium genes have proven useful for heterologous gene expression. Inducible promoters from E.
  • coli such as P lM , and P lu , which are induced by isopropylthiogalactopyranoside (IPTG) when the lac repressor (lacl) is present; P, , which responds to the inducer indole acrylic acid when the trp repressor (trpR) is present; and lambda P, . which is repressed in the presence of the temperature-sensitive lambda repressor (cI857), have all been used to modulate gene expression in Corynebacterium.
  • IPTG isopropylthiogalactopyranoside
  • trpR inducer indole acrylic acid
  • trpR trpR
  • lambda P which is repressed in the presence of the temperature-sensitive lambda repressor (cI857), have all been used to modulate gene expression in Corynebacterium.
  • Transposable Elements are extremely powerful tools in gene identification because they couple mutagenesis with gene recovery. Unlike classical mutagenesis techniques, which generate point mutations or small deletions within a gene, when transposable elements insert within a gene they form large disruptions, thereby "tagging" the altered gene for easier identification. A number of transposable elements have been found to transpose in Corynebacterium. Transposons found in the plasmids pTPIO of C. xerosis and pNG2 of C. diphtheriae have been shown to transpose in C. glutamicum and confer resistance to erythromycin.
  • Transducing Phage Transducing Phage have been used in other systems for mapping genetic loci and for isolating genes. In 1976. researchers at Ajinomoto Co. in Japan surveyed 150 strains of characterized and uncharacterized strains of glutamic acid- producing coryneform bacteria to identify phage that might be useful for transduction (Mornose, H., et al., 1. Gen. Appl. Microbiol Rev. 7(5:243-252 (1995)). Of 24 different phage isolates recovered from this screen, only three were able to transduce a trp marker from a trp + donor to a trp ' recipient with any appreciable frequency, although even this efficiency was only 10 "7 or less.
  • C glutamicum 21253 (horn ' , lysine overproducer) was used for the preparation of chromosomal DNA.
  • Escherichia coli DH5 (hsdR ⁇ , recA ⁇ ) (Hanahan, D., J. Mol. Biol. 7(5(5:557-580 (1983)) was used for transformations.
  • Plasmid pCR2.1 TOPO (Invitrogen) was used for cloning polymerase chain reaction (PCR) products.
  • the plasmid pRR850 was constructed in this study and contained an 850-bp PCR fragment cloned in the pCR2.1 TOPO plasmid.
  • E. coli strains were grown in Luria-Bertani (LB) medium at 37°C (Sambrook, J., et al, Molecular cloning: a laboratory manual. 2nd edn., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY ( 1989)).
  • C. glutamicum was grown in LB medium at 30 °C. Where noted, ampicillin was used at the following concentrations: 100 ⁇ g/ml in plates and 50 ⁇ g/ml in liquid culture.
  • Genomic DNA was isolated from C. glutamicum as described by Tomioka et al. (Tomioka,N., et ⁇ /., o/. Gen. Genet. 754:359-363 (1981)). PCR fragments were cloned into the pCR2.1 TOPO vector following the manufacturer's instructions. Cosmid and plasmid DNA were prepared using Qiaprep spin columns and DNA was extracted from agarose gels with the Qiaex kit (Qiagen). For large-scale high-purity preparation of cosmid DNA for sequencing, the Promega Wizard kit was used (Promega). Standard techniques were used for transformation of E.
  • the cosmid library used was constructed by cloning C. glutamicum chromosomal DNA into the Supercos vector (Stratagene).
  • PCR was performed using the Boehringer Mannheim PCR core kit following the manufacturer's instructions. When PCR was performed on Corynebacterium chromosomal DNA, about 1 ⁇ g DNA was used in each reaction. The forward primer used was
  • Dot blots containing DNA from cosmids identified in this study and the probe as a positive control were prepared using the S&S (Schleicher & Schiill) minifold apparatus. An 850-bp fragment encoding a portion of the C. glutamicum pyruvate carboxylate gene was used as the probe. The probe was labeled with digoxigenin-1 1-dUTP (Boehringer Mannheim) in a randomly primed DNA-labeling reaction as described by the manufacturer. Hybridization, washing and colorimetric detection of the dot blots were done with the Genius system from Boehringer following the protocols in their user's guide for filter hybridization.
  • the initial hybridization with the 291 cosmids was carried out at 65 °C overnight and washes were performed at the hybridization temperature.
  • the hybridization was carried out at 65 °C, but for only 8 h, and the time of exposure to the film was decreased.
  • Cell extracts from C. glutamicum were prepared as described by Jetten and Sinskey (Jetten, M.S.M.. & Sinskey, A ., FEMSMicrobiol Lett. 777: 183-188 (1993)). Proteins in cell extracts were separated in sodium dodecyl sulfate (SDS)/7.5%o polyacrylamide gels in a BioRad mini gel apparatus and were electroblotted onto nitro-cellulose, using the BioRad mini transblot apparatus described by Towbin et al (Towbin, H., et al, Proc. Natl Acad. Sci. USA 7(5:4350-4354 (1979)).
  • SDS sodium dodecyl sulfate
  • Biotinylated proteins were detected using avidin-conjugated alkaline phosphatase from BioRad and 5-bromo-4-chloro-3- indoylphosphate-p-toludine salt/nitroblue tetrazolium chloride from Schleicher & Schiill.
  • the program DNA Strider Version 1.0 (Institut de mecanic Fondamentale, France) was used to invert, complement and translate the DNA sequence, and find open- reading frames in the sequence.
  • the BLAST program (Altschul, S.F.. et al, J. Mol. Biol. 275:403-410 (1990)) from the National Center for Biotechnology Information (NCBI) was employed to compare protein and DNA sequences. Homology searches in proteins were done using the MACAW software (NCBI). PCR primers were designed with the aid of the Primer Premier software from Biosoft International.
  • the compute pI/MW tool on the ExPasy molecular biology server (University of Geneva) was used to predict the molecular mass and pi of the deduced amino acid sequence.
  • Example 1 Western blotting to detect biotinylated enzymes
  • the second band is believed to be the pyruvate carboxylase enzyme, as these proteins are in the range 113-130 kDa (Attwood, P.V., Int. J. Biochem. Cell. Biol. 27:231-249 (1995)).
  • C. glutamicum pyruvate carboxylase gene was cloned on the basis of the homology of highly conserved regions in previously cloned genes. Pyruvate carboxylase genes from thirteen organisms were examined and primers corresponding to an ATP-binding submotif conserved in pyruvate carboxylases and the region close to the pyruvate-binding motif (Table 1) were designed. Where the amino acids were different the primers were designed on the basis of M. tuberculosis because of its close relationship to C. glutamicum. An 850-bp fragment was amplified from C.
  • Example 3 Isolating a cosmid containing the C. glutamicum pyruvate carboxylase gene
  • the 850-base-pair fragment containing a portion of the C. glutamicum pyruvate carboxylase gene was used to probe a C. glutamicum genomic library.
  • 17 out of 291 cosmids in a dot blot appeared positive.
  • a second round of screening was performed on these 17 cosmids, using the same probe but more stringent hybridization conditions, yielding four cosmids with a positive signal.
  • PCR was performed using the four positive cosmids as templates and the same primers used to make the probe.
  • An 850-bp fragment was amplified from all four positive cosmids, designated IIIFIO, IIE9, IIIG7 and IIIB7.
  • the 850-bp insert of plasmid pRR850 was sequenced using the Ml 3 forward and M13 reverse primers. On the basis of this sequence, primers Begrevl and Endforl were designed and used to sequence outwards from the beginning and the end of the 850-bp portion of the pyruvate carboxylase gene. Cosmid III F10 was used as the sequencing template. The sequencing was continued by designing new primers (Table 2) and "walking" across the gene.
  • 3637 bp of cosmid III F10 were sequenced.
  • a 3420-bp open reading frame was identified, which is predicted to encode a protein of 1 140 amino acids.
  • the deduced protein is 63%> identical to M. tuberculosis pyruvate carboxylase and 44%> identical to human pyruvate carboxylase, and the C. glutamicum gene pc was named on the basis of this homology.
  • the deduced protein has a predicted pi of 5.4 and molecular mass of 123.6 kDa, which is similar to the subunit molecular mass of 120 kDa estimated by SDS/polyacrylamide gel electrophoresis.
  • glutamicum pyruvate carboxylase contains the hexapeptide GGGGRG, which matches the GGGG(R/K)G sequence that is found in all biotin-binding proteins and is believed to be an ATP-binding site (Fry, D.C., et al, Proc. Natl Acad. Sci. USA 55:907-91 1 (1986); Post, L.E., et al, J. Biol Chem. 265:1142-1141 (1990)).
  • a second region that is proposed to be involved in ATP binding and is present in biotin-dependent carboxylases and carbamyphosphate synthetase Liim, F., et al, J. Biol. Chem.
  • the predicted C. glutamicum pyruvate carboxylase protein also contains a putative pyruvate-binding motif, FLFEDPWDR. which is conserved in the transcarboxylase domains of Mycobacterium, Rhizobium and human pyruvate carboxylases (Dunn, M.F.. et al, J. Bacteriol. 775:5960-5970 (1996)). Tryptophan fluorescence studies with transcarboxylase have shown that the Trp residue present in this motif is involved in pyruvate binding (Kumer, G.K..
  • the carboxy-terminal segment of the enzyme contains a putative biotin-binding site, AMKM, which is identical to those found in other pyruvate carboxylases as well as the biotin-carboxyl-carrier protein (BCCP) domains of other biotin-dependent enzymes.
  • AMKM putative biotin-binding site
  • the C. glutamicum pyruvate carboxylase protein showed strong homology to M. tuberculosis and the human pyruvate carboxylase (Wexler, I.D., et al, Biochim. Biophys. Ada 7227:46-52 (1994)).
  • C. glutamicum contains more than one enzyme to perform the anaplerotic function of regenerating oxaloacetate.
  • Pseudomonas citronellolis, Pseudomona fluorscens, Azotobacter vinelandii and Thiobacillus novellus contain both ppc and pyruvate carboxylase (O'Brien, R.W., et al, J. Biol. Chem. 252:1257-1263 (1977); Scrutton, M.C. and Taylor, B.L., Arch. Biochem. Biophys.
  • Zea mays contains three isozymes of ppc (Toh, H., et al, Plant Cell Environ. 77:31-43 (1994)) and Saccharomyces cerevisiae contains two isozymes of pyruvate carboxylase (Brewster, N.K., et al, Arch. Biochem. Biophys.
  • citronellolis contains a set of five enzymes that interconvert oxaloacetate, PEP and pyruvate, namely pyruvate kinase, PEP synthetase, PEP carboxylase, oxaloacetate decarboxylase and pyruvate carboxylase (O'Brien, R.W., et al, J. Biol. Chem. 252: 1257-1263 (1977)).
  • Azotobacter contains all of the above enzymes except PEP synthetase (Scrutton, M.C, & Taylor, B.L., Arch. Biochem. Biophys. 764:641-654 (1974)).
  • the entire reading frame from nucleotide 180 to nucleotide 3630 of the pyruvate carboxylase DNA was amplified using PCR.
  • the oligonucleotide primers used for the PCR were designed to remove the Sail site within the coding sequence by silent mutagenesis and introduce EcoRV and Sail sites upstream and downstream, respectively, of the open reading frame.
  • the PCR product was digested with EcoRV and Sail and cloned into the vector pBluescript. The resulting plasmid is pPCBluescript.
  • pPCBluescript a derivative of pPCBluescript was constructed in which the middle portion of the pyc gene was deleted and replaced with the tsr gene, which encodes resistance to the antibiotic thiostrepton.
  • the RP4 mob element was then inserted into the plasmid, yielding pAL240.
  • This plasmid can be conjugally transferred into Corynebacterium, but it is then unable to replicate because it has only a Col ⁇ l origin of replication.
  • pAL240 was transferred from E. coli SI 7-1 into C. glutamicum via transconjugation, and transconjugants were selected on medium containing thiostrepton and nalidixic acid.
  • transconjugants were tested for their ability to grow on different carbon sources. Because pAL240 cannot replicate in C. glutamicum, the only cells which will survive should be those whose genomes have undergone recombination with the plasmid. Several candidates were identified with the proper set of phenotypes: they are resistant to thiostrepton and nalidixic acid, grow well on minimal plates containing glucose or acetate as the sole carbon source, and grow poorly or not at all on minimal plates containing lactate as the sole carbon source.
  • the vector pAPE 12 which has the NG2 origin of replication and a multiple cloning site downstream of the IPTG-controlled trc promoter, was used as an expression vector in C. glutamicum.
  • a derivative of pAPE12 was constructed which contained the pyruvate carboxylase gene downstream of Ptrc.
  • the pyc gene was excised from pPCBluescript using Sail and Xbal and ligated into pAPE 12 which had been cleaved with the same enzymes, forming pLW305.
  • the pyruvate carboxylase gene present in PCBluescript (and hence in pLW305) has the wild type GTG start codon, and the Sail restriction site present near the 5' end of the wild type gene was eliminated by the introduction of a one base silent mutation during amplification of the pyruvate carboxylase gene.
  • pLW305 and pAPE12 was electroporated into several other Corynebacterium genetic backgrounds.
  • a pyruvate carboxylase overexpression plasmid pXL 1 .
  • the 5' end of the gene was amplified from pLW305 with oligonucleotide primers that simultaneously change the GTG start codon to ATG and introduce a BspUJl l-I restriction site, which is compatible with Ncol.
  • the PCR product was then cut with BspUJl l-I and Afel, and ligated into the 7.5 kb backbone obtained by partial digest of pLW305 with Ncol followed by complete cutting with Afel. Two independent sets of ligations and transformations have yielded putative pXLl clones.
  • strains NRRL B-1 1474, NRRL B-11474 (pLW305), and NRRL B- 11474 ⁇ pyc candidate 35 were cultured in flasks on minimal medium for NRRL B-l 1474 with two different sources of carbon: glucose or lactate. The results on growth and amino acid production are presented below.
  • NRRL B-l 1474 and pLW305 show the same behavior on glucose. Both strains produce the same amount of biomass and lysine. On lactate the strains also have similar yield of lysine.
  • NRRL B-l 1474 (pLW305) consumed all of the lactate in the medium ( 17g/l) whereas the wild type NRRL B- 11474 consumed 40%) less lactate during the same period of time.
  • the NRRL B- 1 1474 was calculated to consume lactate at a rate of 0.37 g lactate/hour, whereas the NRRL B-11474 (pLW305) strain consumed this substrate at a rate of 0.65 g lactate/hour.
  • the NRRL B- 1 1474 b ⁇ yc doesn't grow on lactate, which is consistent with the expected phenotype. Its growth on glucose is very low and the strain does not produce lysine. Kinetic studies are conducted to characterize further the behavior of these strains.
  • Pyruvate carboxylase contains biotin. Therefore, it should be possible to detect the accumulation of this enzyme by monitoring the appearance of specific biotinylated products in cells.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne une enzyme anaplérotique provenant de Corynebacterium glutamicum, qui reconstitue l'oxaloacétate consommé durant la production de lysine et d'acide glutamique durant les fermentations industrielles. Elle concerne notamment des molécules d'acide nucléique qui codent pour la protéine pyruvate carboxylase, ainsi que des polypeptides de ladite pyruvate carboxylase.
PCT/US1998/027301 1998-12-23 1998-12-23 PYRUVATE CARBOXYLASE PROVENANT DE $i(CORYNEBACTERIUM GLUTAMICUM) WO2000039305A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
MXPA01006290A MXPA01006290A (es) 1998-12-23 1998-12-23 Piruvato carboxilasa a partir de corynebacterium glutamicum.
EP98966046A EP1147198A1 (fr) 1998-12-23 1998-12-23 Pyruvate carboxylase provenant de corynebacterium glutamicum
CA002356446A CA2356446A1 (fr) 1998-12-23 1998-12-23 Pyruvate carboxylase provenant de corynebacterium glutamicum
CN98814374A CN1336958A (zh) 1998-12-23 1998-12-23 来自谷氨酸棒杆菌的丙酮酸羧化酶
JP2000591196A JP2003503006A (ja) 1998-12-23 1998-12-23 Ｃｏｒｙｎｅｂａｃｔｅｒｉｕｍｇｌｕｔａｍｉｃｕｍ由来のピルビン酸カルボキシラーゼ
AU22033/99A AU2203399A (en) 1998-12-23 1998-12-23 Pyruvate carboxylase from (corynebacterium glutamicum)
BR9816106-7A BR9816106A (pt) 1998-12-23 1998-12-23 Carboxilase de piruvato de corynebacterium glutamicum
PCT/US1998/027301 WO2000039305A1 (fr) 1998-12-23 1998-12-23 PYRUVATE CARBOXYLASE PROVENANT DE $i(CORYNEBACTERIUM GLUTAMICUM)
KR1020017007962A KR20010112232A (ko) 1998-12-23 1998-12-23 코리네박테리움 글루타미컴 유래의 피루베이트 카르복실라제

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/027301 WO2000039305A1 (fr) 1998-12-23 1998-12-23 PYRUVATE CARBOXYLASE PROVENANT DE $i(CORYNEBACTERIUM GLUTAMICUM)

Publications (1)

Publication Number Publication Date
WO2000039305A1 true WO2000039305A1 (fr) 2000-07-06

Family

ID=22268534

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/027301 WO2000039305A1 (fr) 1998-12-23 1998-12-23 PYRUVATE CARBOXYLASE PROVENANT DE $i(CORYNEBACTERIUM GLUTAMICUM)

Country Status (9)

Country Link
EP (1) EP1147198A1 (fr)
JP (1) JP2003503006A (fr)
KR (1) KR20010112232A (fr)
CN (1) CN1336958A (fr)
AU (1) AU2203399A (fr)
BR (1) BR9816106A (fr)
CA (1) CA2356446A1 (fr)
MX (1) MXPA01006290A (fr)
WO (1) WO2000039305A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455284B1 (en) 1998-04-13 2002-09-24 The University Of Georgia Research Foundation, Inc. Metabolically engineered E. coli for enhanced production of oxaloacetate-derived biochemicals
US6965021B2 (en) * 2000-10-13 2005-11-15 Archer-Daniels-Midland Company Feedback-resistant pyruvate carboxylase gene from corynebacterium
DE102008001874A1 (de) 2008-05-20 2009-11-26 Evonik Degussa Gmbh Verfahren zur Herstellung von L-Aminosäuren
DE102008044768A1 (de) 2008-08-28 2010-03-04 Evonik Degussa Gmbh Verfahren zur Herstellung von organisch-chemischen Verbindungen unter Verwendung von verbesserten Stämmen der Familie Enterobacteriaceae
US8202706B2 (en) 2006-07-13 2012-06-19 Evonik Degussa Gmbh Method of production of L-amino acids
EP4183881A4 (fr) * 2020-07-20 2024-04-24 Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences Mutant du promoteur du gène de pyruvate carboxylase et utilisation associée

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100924065B1 (ko) * 2006-09-15 2009-10-27 씨제이제일제당 (주) Ｌ－라이신 생산능이 향상된 코리네박테리아 및 그를 이용한 ｌ－라이신 생산 방법
KR100830826B1 (ko) 2007-01-24 2008-05-19 씨제이제일제당 (주) 코리네박테리아를 이용하여 글리세롤을 포함한탄소원으로부터 발효산물을 생산하는 방법
US8932861B2 (en) 2008-04-10 2015-01-13 Cj Cheiljedang Corporation Transformation vector comprising transposon, microorganisms transformed with the vector, and method for producing L-lysine using the microorganism
KR101126041B1 (ko) 2008-04-10 2012-03-19 씨제이제일제당 (주) 트랜스포존을 이용한 형질전환용 벡터, 상기 벡터로형질전환된 미생물 및 이를 이용한 ｌ-라이신 생산방법
RU2588665C2 (ru) * 2011-12-21 2016-07-10 СиДжей ЧеилДжеданг Корпорейшн Способ получения l-лизина с использованием микроорганизмов, обладающих способностью продуцировать l-лизин
CN103695454A (zh) * 2013-12-18 2014-04-02 山东寿光巨能金玉米开发有限公司 表达l-赖氨酸转运蛋白的重组质粒、工程菌及应用
KR101922113B1 (ko) * 2017-04-25 2018-11-27 한양대학교 산학협력단 패오닥틸럼 트리코누튬 유래 피루브산 전달효소

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0723011A1 (fr) * 1993-08-24 1996-07-24 Ajinomoto Co., Inc. Allele de phosphenolpyruvate carboxylase, gene de cet allele et procede de production de l'acide amine
WO1999018228A2 (fr) * 1997-10-04 1999-04-15 Forschungszentrum Jülich GmbH Procede de preparation microbienne d'aminoacides de la famille de l'aspartate et/ou du glutamate et agents utilisables dans le cadre de l'application dudit procede

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0723011A1 (fr) * 1993-08-24 1996-07-24 Ajinomoto Co., Inc. Allele de phosphenolpyruvate carboxylase, gene de cet allele et procede de production de l'acide amine
WO1999018228A2 (fr) * 1997-10-04 1999-04-15 Forschungszentrum Jülich GmbH Procede de preparation microbienne d'aminoacides de la famille de l'aspartate et/ou du glutamate et agents utilisables dans le cadre de l'application dudit procede

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KOFFAS ET AL.: "Sequence of the Corynebacterium glutamicum pyruvate carboxylase gene", APPL. MICROBIOL. BIOTECHNOL., vol. 50, no. 3, September 1998 (1998-09-01), pages 346 - 352, XP002110411 *
PETERS-WENDISCH ET AL.: "Pyruvate carboxylase as an anaplerotic enzyme in Corynebacterium glutamicum", MICROBIOLOGY, vol. 143, April 1997 (1997-04-01), pages 1095 - 1103, XP002110209 *
PETERS-WENDISCH ET AL.: "Pyruvate carboxylase from Corynebacterium glutamicum: characterization, expression and inactivation of the pyc gene", MICROBIOLOGY, vol. 144, April 1998 (1998-04-01), pages 915 - 927, XP002110208 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455284B1 (en) 1998-04-13 2002-09-24 The University Of Georgia Research Foundation, Inc. Metabolically engineered E. coli for enhanced production of oxaloacetate-derived biochemicals
US6965021B2 (en) * 2000-10-13 2005-11-15 Archer-Daniels-Midland Company Feedback-resistant pyruvate carboxylase gene from corynebacterium
US7300777B2 (en) 2000-10-13 2007-11-27 Archer-Daniels-Midland Company Feedback-resistant pyruvate carboxylase gene from corynebacterium
US8202706B2 (en) 2006-07-13 2012-06-19 Evonik Degussa Gmbh Method of production of L-amino acids
DE102008001874A1 (de) 2008-05-20 2009-11-26 Evonik Degussa Gmbh Verfahren zur Herstellung von L-Aminosäuren
DE102008044768A1 (de) 2008-08-28 2010-03-04 Evonik Degussa Gmbh Verfahren zur Herstellung von organisch-chemischen Verbindungen unter Verwendung von verbesserten Stämmen der Familie Enterobacteriaceae
EP4183881A4 (fr) * 2020-07-20 2024-04-24 Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences Mutant du promoteur du gène de pyruvate carboxylase et utilisation associée

Also Published As

Publication number Publication date
BR9816106A (pt) 2001-09-11
CA2356446A1 (fr) 2000-07-06
EP1147198A1 (fr) 2001-10-24
CN1336958A (zh) 2002-02-20
AU2203399A (en) 2000-07-31
KR20010112232A (ko) 2001-12-20
JP2003503006A (ja) 2003-01-28
MXPA01006290A (es) 2002-04-17

Similar Documents

Publication Publication Date Title
US6884606B2 (en) Pyruvate carboxylase from Corynebacterium glutamicum
AU2019221267B2 (en) Modified polypeptide with attenuated activity of citrate synthase and method for producing L-amino acids using same
KR102150041B1 (ko) 글라이신 생산능이 증가된 미생물 및 이를 이용한 발효 조성물 생산 방법
MXPA02000729A (es) Metodos para la produccion de l-aminoacidos por incremento celular de nadph.
KR20220119026A (ko) 구아니디노아세트산의 발효 생산 방법
CN112143719B (zh) 修饰的高丝氨酸脱氢酶及使用其产生高丝氨酸或衍生自高丝氨酸的l-氨基酸的方法
WO2000039305A1 (fr) PYRUVATE CARBOXYLASE PROVENANT DE $i(CORYNEBACTERIUM GLUTAMICUM)
KR102078732B1 (ko) 변형된 막 투과성
BR112020012963A2 (pt) variante de proteína de receptor de camp e método de produção de l-aminoácido com uso do mesmo
KR102434925B1 (ko) 3-메틸-2-옥소뷰타노에이트 하이드록시 메틸트랜스퍼라아제의 활성이 강화된 미생물, 및 이의 용도
KR101836719B1 (ko) O-아세틸호모세린 설피드릴라제 변이체 및 이를 이용한 l-메치오닌 제조 방법
CN109790557B (zh) 控制生物膜分散以产生氨基酸或氨基酸衍生产物
KR102527895B1 (ko) GlxR 단백질 변이체 또는 이를 이용한 쓰레오닌 생산방법
KR102589135B1 (ko) 3-메틸-2-옥소뷰타노에이트 하이드록시 메틸트랜스퍼라아제의 활성이 강화된 미생물, 및 이의 용도
AU2020426558A1 (en) Novel Modified Polypeptide With Attenuated Activity Of Citrate Synthase And Method For Producing L-Amino Acid Using The Same
KR102031886B1 (ko) 신규한 프로모터 및 이의 용도
KR102688095B1 (ko) 변이형 SpoT 단백질 및 이를 이용한 L-아미노산을 생산하는 방법
KR102016050B1 (ko) 신규한 프로모터 및 이의 용도
KR20220163754A (ko) 신규한 YhhS 변이체 및 이를 이용한 O-포스포세린, 시스테인 및 이의 유도체의 생산방법
KR20220092182A (ko) L-히스티딘 배출 단백질 및 이를 이용한 l-히스티딘 생산 방법

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 98814374.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2356446

Country of ref document: CA

Ref document number: 2356446

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/006290

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2000 591196

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020017007962

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 22033/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998966046

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998966046

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020017007962

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1020017007962

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1998966046

Country of ref document: EP